-

Shareholder Alert: Robbins LLP Is Investigating the Officers and Directors of Vanda Pharmaceuticals Inc. (VNDA)

SAN DIEGO & WASHINGTON--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP announces that it is investigating the officers and directors of Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) for breaches of fiduciary duties, unjust enrichment, and violations of the Securities Exchange Act of 1934. Vanda Pharmaceuticals Inc. is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of central nervous system disorders.

If you suffered a loss as a result of Vanda's misconduct, click here.

Vanda Pharmaceuticals Used its Drugs for Off-Label Purposes

For years, Vanda and its officers hid that Vanda was involved in a fraudulent scheme that included violations of federal Medicare, Medicaid, and Tricare programs and that Vanda's promotional materials were false and misleading, garnering scrutiny from the FDA. Specifically, Vanda schemed to promote its drugs Fanapt and Hetlioz for "off-label" uses in addition to other prohibited promotional strategies. Vanda's executives and officers knew about the prohibited promotional strategies and actively participated in the fraudulent activity. Vanda also issued misleading statements regard tradipitant's clinical trials with the FDA. When the truth was revealed, Vanda's stock declined over 5% and has slipped even more, now trading at just around $11.00. As a result of this conduct, Vanda is facing significant liability from a Qui Tam lawsuit and has already incurred substantial expenses in its investigation. Vanda has also been named as a defendant in a securities class action lawsuit, causing further damage to the company.

Vanda Pharmaceuticals Inc. (VNDA) Shareholders Have Legal Options

Contact us to learn more:
Lauren Levi
(800) 350-6003
llevi@robbinsllp.com
Shareholder Information Form

Robbins LLP is a nationally recognized leader in shareholder rights law. For be notified if a class action against Vanda Pharmaceuticals settles or to receive free alerts about companies engaged in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Lauren Levi
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
llevi@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

More News From Robbins LLP

Robbins LLP Urges PRIM Stockholders to Contact the Firm for Information About the Class Action Against Primoris Services Corporation

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds investors that a securities class action has been filed on behalf of all persons and entities that purchased or otherwise acquired Primoris Services Corporation (NYSE: PRIM) securities between August 5, 2025 and June 22, 2026 (the "Class Period"). The lawsuit alleges that Primoris made materially false or misleading statements regarding the Company's cost forecasting, project oversight, and expected profitability of certain renewable energy constr...

EquipmentShare.com Stock Drop – If You Incurred Significant Losses Investing in EQPT Contact Robbins LLP for Information About Leading the Securities Class Action

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds investors that a securities class action has been filed on behalf of shareholders who purchased or otherwise acquired EquipmentShare.com, Inc. (NASDAQ: EQPT) securities: (1) Class A common stock issued in connection with the Company's January 2026 initial public offering (“IPO”), or (2) EquipmentShare securities between January 23, 2026 and June 23, 2026, inclusive (the “Class Period”). EquipmentShare operates T3, an integrated cloud-based platfor...

MVST Stock Drop – Shareholders Who Suffered Significant Losses Should Contact Robbins LLP for Information About the Securities Class Action Against Microvast Holdings, Inc.

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds investors that a securities class action has been filed on behalf of all persons and entities who purchased or otherwise acquired Microvast Holdings, Inc. (NASDAQ: MVST) securities between April 1, 2025 and March 16, 2026, inclusive (the “Class Period”). The lawsuit alleges that Microvast Holdings, Inc. misled investors about its ability to achieve targeted profit margins and complete the expansion of its Huzhou, China manufacturing facility on sc...
Back to Newsroom